Clinical trials on the use of Ivermectin as a Covid-19 treatment may be finished by April next year, but their results could come out as early as December, the Department of Science and Technology (DoST) said Saturday.
DoST Secretary Fortunato de la Peña said Philippine trials officially started mid-August 2021 and were expected to be completed in eight months.
“That is actually relatively shorter compared to other clinical trials. This is because of simultaneous recruitment, and the short duration of treatment,” De la Peña said.
“If we count by eight months, the trials will be finished by April (2022). But those conducting the clinical trials reported that if the recruitment is simultaneous and the duration of treatment is short, perhaps within six months it could be finished, by December we can have an analysis,” he added.
The trials include double-blind, placebo-controlled, parallel-group and randomized clinical tests with three intervention arms, he explained. The first treatment group is given placebo drugs once a day for five days, while the second treatment group is given 400 mcg of Ivermectin per kilogram per day, once a day for five days.
The third treatment arm is administered 600 mcg of Ivermectin per kilogram per day, once a day for five days.